Combining stem cells and exon skipping strategy to treat muscular dystrophy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Muscular dystrophies are a group of diseases characterized by the primary wasting of skeletal muscle. Mutations in the dystrophin gene cause Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The characterization of the dystrophin gene and the evidence that adult stem cells are capable of participating into regeneration of more than its resident organ has lead to the development of potential gene therapy and stem cells treatments for this disorder. The combination of gene therapy and stem cell therapy may represent a very promising strategy. In this chapter, we describe an example of such combined therapy. We first corrected mutation in DMD pateints' stem cells with antisense oligonucelotide mediated exon skipping. The corrected stem cells were then delivered to the mdx mouse model via intra-arterial injection. This approach has several advantages. Intravascular delivery distributes the stem cells to the whole body musculature. The use of the autologous transplantation minimizes the risk of immunological graft rejection.

Original languageEnglish
Title of host publicationMuscle Gene Therapy
PublisherSpringer New York
Pages249-256
Number of pages8
ISBN (Print)9781441912077, 9781441912053
DOIs
Publication statusPublished - 2010

Fingerprint

Muscular Dystrophies
Stem cells
Exons
Stem Cells
Duchenne Muscular Dystrophy
Dystrophin
Gene therapy
Genetic Therapy
Inbred mdx Mouse
Intra-Arterial Injections
Genes
Mutation
Adult Stem Cells
Autologous Transplantation
Transplantation (surgical)
Graft Rejection
Cell- and Tissue-Based Therapy
Regeneration
Skeletal Muscle
Grafts

Keywords

  • Adult stem cells
  • AON
  • DMD
  • Exon skipping
  • Muscular dystrophies
  • Viral vectors

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Combining stem cells and exon skipping strategy to treat muscular dystrophy. / Meregalli, Mirella; Farini, Andrea; Torrente, Yvan.

Muscle Gene Therapy. Springer New York, 2010. p. 249-256.

Research output: Chapter in Book/Report/Conference proceedingChapter

Meregalli, Mirella ; Farini, Andrea ; Torrente, Yvan. / Combining stem cells and exon skipping strategy to treat muscular dystrophy. Muscle Gene Therapy. Springer New York, 2010. pp. 249-256
@inbook{12dd9be7fe644cc6a6b2311256607c9e,
title = "Combining stem cells and exon skipping strategy to treat muscular dystrophy",
abstract = "Muscular dystrophies are a group of diseases characterized by the primary wasting of skeletal muscle. Mutations in the dystrophin gene cause Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The characterization of the dystrophin gene and the evidence that adult stem cells are capable of participating into regeneration of more than its resident organ has lead to the development of potential gene therapy and stem cells treatments for this disorder. The combination of gene therapy and stem cell therapy may represent a very promising strategy. In this chapter, we describe an example of such combined therapy. We first corrected mutation in DMD pateints' stem cells with antisense oligonucelotide mediated exon skipping. The corrected stem cells were then delivered to the mdx mouse model via intra-arterial injection. This approach has several advantages. Intravascular delivery distributes the stem cells to the whole body musculature. The use of the autologous transplantation minimizes the risk of immunological graft rejection.",
keywords = "Adult stem cells, AON, DMD, Exon skipping, Muscular dystrophies, Viral vectors",
author = "Mirella Meregalli and Andrea Farini and Yvan Torrente",
year = "2010",
doi = "10.1007/978-1-4419-1207-7_15",
language = "English",
isbn = "9781441912077",
pages = "249--256",
booktitle = "Muscle Gene Therapy",
publisher = "Springer New York",

}

TY - CHAP

T1 - Combining stem cells and exon skipping strategy to treat muscular dystrophy

AU - Meregalli, Mirella

AU - Farini, Andrea

AU - Torrente, Yvan

PY - 2010

Y1 - 2010

N2 - Muscular dystrophies are a group of diseases characterized by the primary wasting of skeletal muscle. Mutations in the dystrophin gene cause Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The characterization of the dystrophin gene and the evidence that adult stem cells are capable of participating into regeneration of more than its resident organ has lead to the development of potential gene therapy and stem cells treatments for this disorder. The combination of gene therapy and stem cell therapy may represent a very promising strategy. In this chapter, we describe an example of such combined therapy. We first corrected mutation in DMD pateints' stem cells with antisense oligonucelotide mediated exon skipping. The corrected stem cells were then delivered to the mdx mouse model via intra-arterial injection. This approach has several advantages. Intravascular delivery distributes the stem cells to the whole body musculature. The use of the autologous transplantation minimizes the risk of immunological graft rejection.

AB - Muscular dystrophies are a group of diseases characterized by the primary wasting of skeletal muscle. Mutations in the dystrophin gene cause Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The characterization of the dystrophin gene and the evidence that adult stem cells are capable of participating into regeneration of more than its resident organ has lead to the development of potential gene therapy and stem cells treatments for this disorder. The combination of gene therapy and stem cell therapy may represent a very promising strategy. In this chapter, we describe an example of such combined therapy. We first corrected mutation in DMD pateints' stem cells with antisense oligonucelotide mediated exon skipping. The corrected stem cells were then delivered to the mdx mouse model via intra-arterial injection. This approach has several advantages. Intravascular delivery distributes the stem cells to the whole body musculature. The use of the autologous transplantation minimizes the risk of immunological graft rejection.

KW - Adult stem cells

KW - AON

KW - DMD

KW - Exon skipping

KW - Muscular dystrophies

KW - Viral vectors

UR - http://www.scopus.com/inward/record.url?scp=84919864988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919864988&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-1207-7_15

DO - 10.1007/978-1-4419-1207-7_15

M3 - Chapter

AN - SCOPUS:84919864988

SN - 9781441912077

SN - 9781441912053

SP - 249

EP - 256

BT - Muscle Gene Therapy

PB - Springer New York

ER -